KFDA to approve Boehringer Ingelheim’s novel, oral anticoagulant
Published: 2011-02-14 06:58:00
Updated: 2011-02-14 06:58:00
The Korea Food and Drug Administration is likely to approve Pradaxa (dabigatran etexilate), Boehringer Ingelheim’s novel, oral direct thrombin inhibitor for stroke risk reduction in patients with non-valvular atrial fibrillation (AF) within this month.
This new treatment will improve the lives...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
